The Board approved AFR for the qtr/year ended 31 March 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts less than Nifty Microcap 250 and 0.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Brawn Biotech's board approved audited financial results for Q4 and full year ended March 31, 2025. Revenue from operations for FY25 stood at Rs 1,346.50 lakhs, down from Rs 1,609.47 lakhs in FY24, marking a decline of roughly 16%. The company reported a net loss of Rs 179.84 lakhs for FY25, wider than the Rs 164.42 lakh loss in FY24. Q4 FY25 revenue was Rs 225.93 lakhs versus Rs 244.65 lakhs in Q4 FY24. Basic EPS worsened to Rs (5.87) from Rs (5.14) a year ago. Other equity shrank sharply from Rs 206.47 lakhs to Rs 36.20 lakhs as accumulated losses continue to eat into reserves. The statutory auditor, Rajiv Udai & Associates, issued an unmodified (clean) opinion on the results.
Persistent losses, shrinking top line and steady erosion of shareholder equity are negative signals for retail investors; the stock may continue to face pressure. The clean audit opinion offers limited comfort, but no turnaround indicators are visible in these numbers.